- Home
- ACB vs CRDF Comparison
ACB vs CRDF Comparison
Compare ACB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- CRDF
- Stock Information
- Founded
- ACB 2013
- CRDF 1999
- Country
- ACB Canada
- CRDF United States
- Employees
- ACB N/A
- CRDF N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACB Health Care
- CRDF Health Care
- Exchange
- ACB Nasdaq
- CRDF Nasdaq
- Market Cap
- ACB 257.9M
- CRDF 240.2M
- IPO Year
- ACB N/A
- CRDF N/A
- Fundamental
- Price
- ACB $3.85
- CRDF $3.45
- Analyst Decision
- ACB Hold
- CRDF Strong Buy
- Analyst Count
- ACB 1
- CRDF 3
- Target Price
- ACB N/A
- CRDF $10.33
- AVG Volume (30 Days)
- ACB 739.6K
- CRDF 1.4M
- Earning Date
- ACB 02-06-2025
- CRDF 02-27-2025
- Dividend Yield
- ACB N/A
- CRDF N/A
- EPS Growth
- ACB N/A
- CRDF N/A
- EPS
- ACB N/A
- CRDF N/A
- Revenue
- ACB $219,835,671.00
- CRDF $688,000.00
- Revenue This Year
- ACB $19.90
- CRDF $25.03
- Revenue Next Year
- ACB $5.80
- CRDF N/A
- P/E Ratio
- ACB N/A
- CRDF N/A
- Revenue Growth
- ACB 13.15
- CRDF 49.57
- 52 Week Low
- ACB $2.84
- CRDF $1.44
- 52 Week High
- ACB $9.35
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- ACB 33.62
- CRDF 45.05
- Support Level
- ACB $3.91
- CRDF $3.33
- Resistance Level
- ACB $4.85
- CRDF $4.89
- Average True Range (ATR)
- ACB 0.22
- CRDF 0.31
- MACD
- ACB -0.04
- CRDF -0.15
- Stochastic Oscillator
- ACB 0.99
- CRDF 10.56
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").